US health chief says there is not enough data to show Tylenol causes autism

Investing.comWednesday, October 29, 2025 at 8:44:14 PM
US health chief says there is not enough data to show Tylenol causes autism
The US health chief has stated that there is insufficient data to establish a link between Tylenol and autism. This clarification is important as it addresses ongoing concerns among parents and healthcare professionals regarding the safety of common medications. By emphasizing the lack of evidence, it helps to alleviate fears and encourages informed decision-making about pain relief options.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Opinion | Ken Paxton Bellies Up to the Trial Bar
NegativeFinancial Markets
Texas Attorney General Ken Paxton is intensifying his anti-business campaign by targeting the makers of Tylenol. This move raises concerns about the implications for businesses operating in Texas, as it signals a potentially hostile environment for companies facing legal challenges. The trial bar's involvement could lead to increased litigation, affecting not only the pharmaceutical industry but also the broader business landscape in the state.
Canaccord downgrades Tylenol maker Kenvue as legal risks cloud turnaround
NegativeFinancial Markets
Canaccord has downgraded Kenvue, the maker of Tylenol, citing increasing legal risks that could hinder the company's turnaround efforts. This decision reflects concerns about potential liabilities that may impact Kenvue's financial performance and market position. Investors and stakeholders should pay attention to these developments as they could influence the company's future strategies and stock performance.
Texas Sues Tylenol Makers, Claiming They Hid Autism Risks
NegativeFinancial Markets
Texas has filed a lawsuit against Tylenol manufacturers Johnson & Johnson and Kenvue, alleging that they concealed risks linking acetaminophen use during pregnancy to autism. This lawsuit comes in the wake of controversial claims made by former President Trump, which have not been scientifically validated. The outcome of this case could have significant implications for public health and the pharmaceutical industry, as it raises questions about the safety of widely used medications during pregnancy.
Texas sues Tylenol makers J&J and Kenvue, claiming they hid drug’s autism risks
NegativeFinancial Markets
Texas has filed a lawsuit against Tylenol manufacturers Johnson & Johnson and Kenvue, alleging that they concealed risks associated with the drug that could lead to autism. This case is significant as it raises concerns about the transparency of pharmaceutical companies regarding the safety of their products, potentially impacting public trust and health policies.
Texas sues Tylenol makers alleging deceptive marketing to pregnant people
NegativeFinancial Markets
Texas Attorney General Ken Paxton has filed a lawsuit against Tylenol's manufacturers, Johnson & Johnson and Kenvue, alleging that they misled pregnant individuals about the safety of acetaminophen. This lawsuit follows controversial claims linking the medication to autism and ADHD in children, raising significant concerns about the marketing practices of pharmaceutical companies. The outcome could have major implications for public health and consumer trust in medication safety.
Embattled ​Tylenol Maker Kenvue Hires New Marketing Chief
NegativeFinancial Markets
Kenvue, the maker of Tylenol, is facing a significant crisis as concerns grow about potential links between its product and autism. In response, the company has decided to hire Jon Halvorson, a seasoned executive from the snack food industry, as its new marketing chief. This move is crucial for Kenvue as it seeks to navigate the challenges posed by these serious allegations and restore consumer trust in its brand.
Texas Sues Kenvue, Alleging Omission of Autism Link From Tylenol Marketing
NegativeFinancial Markets
Texas has filed a lawsuit against Kenvue, the maker of Tylenol, claiming that the company misled consumers by promoting the pain reliever as safe for use during pregnancy without disclosing potential links to autism. This case raises significant concerns about the responsibility of pharmaceutical companies in marketing their products and the implications for public health, especially for expectant mothers.
Latest from Financial Markets
Signs Point to Client Confidence: Edward Jones' Pennington
PositiveFinancial Markets
Penny Pennington, the Managing Partner at Edward Jones, recently shared insights on market volatility during an interview on 'The Close' with Katie Greifeld and Romaine Bostick. She noted that clients are not only aware of the potential for market swings but are also ready to seize opportunities that arise from them. This proactive approach reflects a growing confidence among investors, which is crucial for market stability and growth.
See Growth Opportunities in LatAm: Mercadolibre CFO
PositiveFinancial Markets
MercadoLibre's CFO, Martin de los Santos, recently shared exciting insights about the company's growth potential in Latin America. By leveraging AI, MercadoLibre is empowering its 20,000 developers to be more proactive, which is crucial for enhancing their platform. This investment in technology not only positions the company for future success but also highlights the increasing importance of AI in driving innovation in the region.
Digicel CEO on the Impact of Hurricane Melissa
PositiveFinancial Markets
Marcelo Cataldo, the CEO of Digicel, highlights the potential for growth in smartphone adoption in the Caribbean, which currently trails behind regions like Latin America and Europe. In a conversation on 'The Close,' he emphasizes the opportunity to enhance connectivity and data usage, suggesting that many users still depend on voice services. This insight is crucial as it points to a significant market potential that could lead to improved communication and economic development in the region.
Earnings call transcript: Ford Q3 2025 earnings beat expectations, stock surges
PositiveFinancial Markets
Ford's Q3 2025 earnings report has exceeded expectations, leading to a significant surge in its stock price. This positive financial performance highlights the company's strong market position and effective strategies, which are crucial for investors and stakeholders. As Ford continues to innovate and adapt to market demands, this earnings beat not only boosts investor confidence but also sets a promising tone for future growth.
GoDaddy Q3 2025 slides: revenue up 10%, AI initiatives accelerate growth
PositiveFinancial Markets
GoDaddy has reported a 10% increase in revenue for Q3 2025, highlighting the effectiveness of its AI initiatives in driving growth. This positive trend not only reflects the company's strong performance but also underscores the increasing importance of technology in enhancing business operations. As GoDaddy continues to innovate, it sets a benchmark for others in the industry, showcasing how embracing AI can lead to substantial financial gains.
Earnings call transcript: Old Republic beats Q3 2025 EPS, stock fluctuates
PositiveFinancial Markets
Old Republic has reported a strong performance in its Q3 2025 earnings call, surpassing expectations with a higher-than-anticipated earnings per share (EPS). This positive news has led to fluctuations in the stock price, reflecting investor interest and confidence in the company's future. Such results are significant as they indicate the company's resilience and potential for growth in a competitive market.